About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...

MagnetisMM-32 is an open-label, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of ELREXFIO monotherapy versus investigator’s choice among three standard-of-care regimens ...

Pfizer is a well-established name that’s proud to shape Ireland’s thriving pharmaceuticals industry. We are home to around 3,700 people in six sites in Ireland, delivering skills across manufacturing, ...

It started with a breakthrough. The year was 1849, and people everywhere were getting sick to their stomachs. In the days before widespread refrigeration, a simple meal of meat and potatoes could ...

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned ...

Pfizer offers competitive compensation and benefits based on a variety of factors including prior experience, geographic location, and talent pool availability: ...

Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer ...

As Pfizer’s strategic corporate venture capital arm, Pfizer Ventures invests globally in innovative biopharmaceutical companies advancing breakthrough medicines that have the potential to transform ...

We can't wait for you to join us! To help you prepare, we’ve created an onboarding experience that will get you ready for day one, give you an opportunity to learn more about the business, and start ...

This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may ONLY respond to calls and emails ...

Roughly one in three Americans is at risk for heart failure 1, a condition where the heart can no longer effectively pump blood. And one in four will develop heart failure at some point in their lives ...

Full-Year 2024 Revenue Guidance (1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition Anticipates Approximately $8 Billion in Revenues for Comirnaty (2) and ...